SCHEMBL5390907

SCHEMBL5390907

NC(=O)CCCC(NC(=O)[CH]CS(=O)(=O)Cc1ccccc1OC(F)F)C(=O)c1nnc(-c2cccnc2)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.37
CES1 P23141 1/20 0.37
ELANE P08246 1/20 0.35
CTSK P43235 5/20 0.34
ALDH1A1 P00352 1/20 0.33
CA2 P00918 1/20 0.33
CTSS P25774 4/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
STAT1 P42224 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
CTSL P07711 2/20 0.31
CTSB P07858 2/20 0.31
POLB P06746 1/20 0.31
LMNA P02545 1/20 0.31
EGFR P00533 1/20 0.31
PTGS2 P35354 1/20 0.31
KDM4E B2RXH2 2/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5394089 0.86 CES1 (0.47) FAAHCES1ELANECTSKALDH1A1
SCHEMBL5392503 0.81 ALDH1A1 (0.35) FAAHCES1ELANEALDH1A1CA2
SCHEMBL5390908 0.81 CTSK (0.43) FAAHCES1ELANECTSKALDH1A1
SCHEMBL5399987 0.80 CTSK (0.43) FAAHCES1CTSKALDH1A1CTSS
SCHEMBL5400589 0.80 CTSK (0.43) FAAHCES1CTSKALDH1A1CTSS
SCHEMBL5397960 0.80 CTSK (0.43) FAAHCES1CTSKALDH1A1CTSS
SCHEMBL14427089 0.74 CTSS (0.41) ELANECTSKCTSSNPC1RAB9A
SCHEMBL5392508 0.71 ALDH1A1 (0.36) FAAHCES1ELANEALDH1A1CA2
SCHEMBL14489144 0.68 CTSS (0.42) CTSKCTSSNPC1RAB9ACTSL
SCHEMBL14427113 0.66 CTSS (0.39) FAAHCES1ELANEALDH1A1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203138-A1 Novel Compounds and Compositions as Cathepsin S Inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-08-30 US claimed
US-7226921-B2 Compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-06-05 US claimed
US-6977256-B2 Compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 US claimed
US-20050267044-A1 Novel compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US claimed
EP-1446392-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2004-08-18 EP claimed
US-20030199506-A1 Novel compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS INC. 2003-10-23 US claimed
WO-2003042197-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2003-05-22 WO claimed
US-20070203138-A1 Novel Compounds and Compositions as Cathepsin S Inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-08-30 US disclosed
US-7226921-B2 Compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-06-05 US disclosed
US-6977256-B2 Compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 US disclosed
US-20050267044-A1 Novel compounds and compositions as cathepsin S inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US disclosed
EP-1446392-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2004-08-18 EP disclosed
US-20030199506-A1 Novel compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS INC. 2003-10-23 US disclosed
WO-2003042197-A1 OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2003-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267044-A1 Novel compounds and compositions as cathepsin S inhibitors CTSS, CTSB, CTSE FAAH 635/4885CES1 173/4885ELANE 61/4885
US-20070203138-A1 Novel Compounds and Compositions as Cathepsin S Inhibitors CTSS, CTSB, CTSE FAAH 635/4885CES1 173/4885ELANE 61/4885
US-20030199506-A1 Novel compounds and compositions as cathepsin S inhibitors CTSS, CTSB, CTSE FAAH 576/4885CES1 104/4885ELANE 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.